166 related articles for article (PubMed ID: 32421352)
21. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
[No Abstract] [Full Text] [Related]
22. Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis.
McNally P; Butler D; Karpievitch YV; Linnane B; Ranganathan S; Stick SM; Hall GL; Schultz A
Am J Respir Crit Care Med; 2021 Sep; 204(5):605-608. PubMed ID: 34077699
[No Abstract] [Full Text] [Related]
23. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype.
Clancy JP; Johnson SG; Yee SW; McDonagh EM; Caudle KE; Klein TE; Cannavo M; Giacomini KM;
Clin Pharmacol Ther; 2014 Jun; 95(6):592-7. PubMed ID: 24598717
[TBL] [Abstract][Full Text] [Related]
24. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.
O'Reilly R; Elphick HE
Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402
[TBL] [Abstract][Full Text] [Related]
25. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
Trimble AT; Donaldson SH
J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
Davies JC; Wainwright CE; Canny GJ; Chilvers MA; Howenstine MS; Munck A; Mainz JG; Rodriguez S; Li H; Yen K; Ordoñez CL; Ahrens R;
Am J Respir Crit Care Med; 2013 Jun; 187(11):1219-25. PubMed ID: 23590265
[TBL] [Abstract][Full Text] [Related]
27. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
[TBL] [Abstract][Full Text] [Related]
28. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
29. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
30. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
31. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
Ramsey BW; Davies J; McElvaney NG; Tullis E; Bell SC; Dřevínek P; Griese M; McKone EF; Wainwright CE; Konstan MW; Moss R; Ratjen F; Sermet-Gaudelus I; Rowe SM; Dong Q; Rodriguez S; Yen K; Ordoñez C; Elborn JS;
N Engl J Med; 2011 Nov; 365(18):1663-72. PubMed ID: 22047557
[TBL] [Abstract][Full Text] [Related]
32. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
33. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
34. Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function.
Salvatore D; Terlizzi V; Francalanci M; Taccetti G; Messore B; Biglia C; Pisi G; Calderazzo MA; Caloiero M; Pizzamiglio G; Majo F; Cresta F; Leonetti G; De Venuto D
Respir Med; 2020 Sep; 171():106073. PubMed ID: 32846335
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
[No Abstract] [Full Text] [Related]
36. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.
Rowe SM; Daines C; Ringshausen FC; Kerem E; Wilson J; Tullis E; Nair N; Simard C; Han L; Ingenito EP; McKee C; Lekstrom-Himes J; Davies JC
N Engl J Med; 2017 Nov; 377(21):2024-2035. PubMed ID: 29099333
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
[TBL] [Abstract][Full Text] [Related]
38. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
Elborn JS; Ramsey B; Wainwright C; Boyle M
Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
[No Abstract] [Full Text] [Related]
39. Ivacaftor CFTR Potentiator Therapy is Efficient for Pancreatic Manifestations in Cystic Fibrosis.
Kounis I; Lévy P; Rebours V
Am J Gastroenterol; 2018 Jul; 113(7):1058-1059. PubMed ID: 29887601
[No Abstract] [Full Text] [Related]
40. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
